argenx NV ADR (ARGX)
NASDAQ · Healthcare · Biotechnology
argenx NV ADR is a Healthcare company with a market capitalization of $53.23B and a trailing P/E ratio of 32.7.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in EUR
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $4.70 | $4.19 | +12.2% |
| Q4 2025 | February 26, 2026 | $8.02 | $6.24 | +28.5% |
| Q3 2025 | October 30, 2025 | $4.44 | $3.54 | +25.4% |
| Q2 2025 | July 31, 2025 | $3.26 | $2.61 | +24.9% |
| Q1 2025 | May 8, 2025 | $2.27 | $2.05 | +10.7% |
| Q4 2024 | March 31, 2025 | $0.71 | $1.70 | -58.0% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 1,539,375 | — | 5.1 | +6.1% |
| June 30, 2026 | 1,450,472 | — | 3.5 | -1.1% |
| June 15, 2026 | 1,466,999 | — | 3.9 | -18.8% |
| May 29, 2026 | 1,807,173 | — | 6.9 | -16.0% |
| May 15, 2026 | 2,150,508 | — | 6.2 | +3.5% |
| April 30, 2026 | 2,077,333 | — | 7.2 | -9.0% |
| April 15, 2026 | 2,283,168 | — | 7.3 | +2.4% |
| March 31, 2026 | 2,230,300 | — | 6.8 | +18.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is argenx NV ADR's market cap?
As of August 13, 2026, argenx NV ADR (ARGX) has a market capitalization of $53.23B.
What is argenx NV ADR's P/E ratio?
argenx NV ADR trades at a trailing price-to-earnings (P/E) ratio of 32.7. Its forward P/E is 30.4.
Does argenx NV ADR pay a dividend?
argenx NV ADR does not currently pay a dividend.
What sector is ARGX in?
argenx NV ADR is in the Healthcare sector, specifically the Biotechnology industry.
What is argenx NV ADR's short interest?
As of the July 15, 2026 FINRA settlement, 1,539,375 ARGX shares were sold short. Days to cover: 5.1. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was argenx NV ADR's revenue?
In its latest reported fiscal year (ending December 31, 2025), argenx NV ADR reported revenue of 4.15B EUR and net income of 1.29B EUR.
Ask your own questions about ARGX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.